Neurotech Accelerates Pediatric Cannabinoid Therapy with European Partner

Strategic Partnership to Advance Pediatric Cannabinoid Therapies

Neurotech International Limited (ASX: NTI), a clinical-stage biopharmaceutical company specialising in pediatric neurological disorders, has announced a binding development agreement with RH Farma Dooel Skopje (RH Pharma), a subsidiary of the European Cannabis Company (ECC). This collaboration aims to develop a pharmaceutical-grade, broad-spectrum cannabinoid drug product designed specifically for children with neurodevelopmental disorders such as autism, Rett Syndrome, and PANDAS/PANS.

RH Pharma brings to the table its proprietary CO2 extraction technology and GMP-certified manufacturing capabilities, enabling the production of consistent, high-quality cannabinoid formulations. The partnership is set to leverage RH Pharma’s expertise in controlled recombination of purified cannabinoids from standard cannabis strains, ensuring the final product meets stringent global regulatory standards.

Meeting Global Demand with Quality and Compliance

Neurotech’s CEO, Dr Anthony Filippis, emphasised the importance of scaling production to meet anticipated demand following regulatory approvals, particularly for their lead candidate NTI64. The agreement includes an upfront payment of €25,000 and outlines a 12-month initial term, with additional services to be provided as requested by Neurotech. This arrangement not only supports the company’s provisional registration strategy in Australia but also positions Neurotech to expand its footprint internationally.

RH Pharma’s recent renewal of its EU German GMP certification underscores its capacity to produce up to 8 tonnes of GMP-grade medical cannabis flower and over 250,000 bottles of GMP-grade extract annually. This scale and quality assurance are critical for Neurotech’s ambitions to deliver consistent, strain-agnostic cannabinoid therapies that align with their proprietary compositional standards.

Innovation and Clinical Validation at the Forefront

Neurotech’s cannabinoid formulations have demonstrated statistically significant clinical benefits in Phase II/III trials for Autism Spectrum Disorder and Phase I/II trials for PANDAS/PANS and Rett Syndrome. The company’s commitment to innovation is further reflected in ongoing clinical trials, including a Phase I/II study in spastic cerebral palsy. The collaboration with ECC and RH Pharma is expected to accelerate product development timelines and enhance the company’s ability to meet regulatory and market demands.

Rebeka Levy, General Manager of ECC, highlighted the shared vision for innovation and international expansion, positioning the partnership to meet the growing global demand for high-quality cannabis-based pharmaceuticals. This alliance represents a strategic step for Neurotech to solidify its leadership in the pediatric cannabinoid therapy space.

Looking Ahead

As Neurotech advances its development program with RH Pharma, the company is poised to address an underserved market segment with significant unmet medical needs. The collaboration underscores the increasing convergence of biopharmaceutical innovation and cannabis-derived therapies, setting a precedent for future partnerships in this evolving sector.